Abstract:The gastrointestinal (GI) tract of a fetus in utero is sterile but it becomes colonized with environmental microorganisms shortly after birth. Since the gut microbiota undergoes substantial changes in early life, healthy gut microflora is essential to an infant's gut health and immune system and probably also has an effect on overall health status in later life. Probiotics, defined as viable microbial preparations that have a beneficial effect on the health of the host, represent a rapidly expanding field. Although randomized controlled trials using probiotics in infants have shown promising results in the prevention and treatment of common diseases such as diarrhea and allergy, little is known about whether probiotics could offer benefits to healthy infants. We have designed a randomized controlled trial to test the hypothesis that an oral preparation of probiotics is superior to placebo in improving digestive and immune function in healthy infants.The trial will be a randomized, double-blind, placebo-controlled, 2-parallel-group study in Shanghai, China. After a 2-week run-in period, 200 exclusively formula-fed healthy infants aged 4 to 6 months will be randomly allocated to receive either a probiotic product containing Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052 or an identical placebo once daily for 4 weeks and will be followed up for 8 weeks. The duration of the subject's participation will be 14 weeks, with a total of 5 visits: inclusion (Visit 1, Day 1), start of intervention (V2, D15), end of intervention (V3, D44), and follow-up (V4 and V5, D72 and D100). Stool and saliva samples will be collected at the first 3 visits to measure microbial populations and secretory immunoglobulin A (SIgA), respectively. Physical examination will be performed at each visit, and tolerance records will be completed 1 day prior to each visit. The primary endpoints will be the changes in the composition of fecal microbiota, particularly the Bifidobacterium bifidum population. The secondary endpoints will include the change in salivary SIgA level, growth parameters, digestive tolerance, and adverse events.An effective, practical, and acceptable probiotic intervention in manipulating the gut microbiota and boosting the immune system in formula-fed infants would represent a major clinical advance. The administration of probiotic supplementation or follow-on formula to infant may be associated with some clinic benefits.

Probiotics Induce Intestinal IgA Secretion in Weanling Mice Potentially Through Promoting Intestinal APRIL Expression and Modulating the Gut Microbiota Composition.

Bifidobacterium longum Subsp. infantis Promotes IgA Level of Growing Mice in a Strain-Specific and Intestinal Niche-Dependent Manner

Sex-Dependent Modulation Of Immune Development In Mice By Secretory Iga-Coated Lactobacillus Reuteri Isolated From Breast Milk

Prevention of Atopic Dermatitis in Mice by <i>Lactobacillus Reuteri</i> Fn041 Through Induction of Regulatory T Cells and Modulation of the Gut Microbiota

Positive Effects of a Clostridium Butyricum-Based Compound Probiotic on Growth Performance, Immune Responses, Intestinal Morphology, Hypothalamic Neurotransmitters, and Colonic Microbiota in Weaned Piglets

Effect of Orally Administered Enterococcus Faecium Ef1 on Intestinal Cytokines and Chemokines Production of Suckling Piglets

Supplementing Maternal Diet with Milk Oligosaccharides and Probiotics Helps Develop the Immune System and Intestinal Flora of Offsprings

Effect of Probiotics on Digestibility and Immunity in Infants

IgA-mediated control of host-microbial interaction during weaning reaction influences gut inflammation

The Enhancement of Intestinal Immunity in Offspring Piglets by Maternal Probiotic or Synbiotic Supplementation Is Associated With the Alteration of Gut Microbiota

Intestinal Microbiota Succession And Immunomodulatory Consequences After Introduction Of Lactobacillus Reuteri I5007 In Neonatal Piglets

Lactobacillus Rhamnosus Alters Intestinal IgA Levels and IgA–microbiota Interactions in Healthy Mice in a Strain-Specific Manner

Oral administration of Bifidobacterium bifidum TMC3115 to neonatal mice may alleviate IgE-mediated allergic risk in adulthood.

Probiotics and antimicrobial protein and peptide levels in preterm infants

Dietary Probiotics Or Synbiotics Supplementation During Gestation, Lactation, And Nursery Periods Modifies Colonic Microbiota, Antioxidant Capacity, And Immune Function In Weaned Piglets

Lactobacillus derived from breast milk facilitates intestinal development in IUGR rats

Akkermansia Muciniphila Promotes SIgA Production and Alters the Reactivity Towards Commensal Bacteria in Early-Weaned Piglets

A. muciniphila Supplementation in Mice during Pregnancy and Lactation Affects the Maternal Intestinal Microenvironment

Probiotics Lactobacillus rhamnosus GG ATCC53103 and Lactobacillus plantarum JL01 induce cytokine alterations by the production of TCDA, DHA, and succinic and palmitic acids, and enhance immunity of weaned piglets.

Co-administration of Bacillus subtilis RJGP16 and Lactobacillus salivarius B1 strongly enhances the intestinal mucosal immunity of piglets.

The Probiotic Strain Bifidobacterium animalis ssp. lactis HY8002 Potentially Improves the Mucosal Integrity of an Altered Intestinal Microbial Environment